Full-Time

Senior Manager-SAP BTP Platform Services

Posted on 2/21/2026

Deadline 2/27/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$137k - $235.8k/yr

Bridgewater Township, NJ, USA + 1 more

More locations: Edison, NJ, USA

In Person

Category
Engineering Management (1)
Required Skills
SAP Products
Requirements
  • Bachelor's degree is required preferably in Information Systems or Computer Science, or a relevant field.
  • Master's degree is preferred.
  • 14 years of experience as a System Architect supporting SAP applications and platforms with understanding of servers, applications architecture, system connectivity, platform design, storage, databases and compliance processes.
  • Experience supporting SAP application and platform with understanding of servers, applications architecture, system connectivity, platform design, storage, databases and Compliance Process required.
  • Current and/or prior people management experience required.
  • Knowledge of business processes in SAP/other ERP services preferred.
  • Knowledge of Front end tool using FIORI, UI5, Knowledge on Integration design preferred.
  • SAP BTP App Development & Integration, BTP Architecture and Design, S4 HANA, SAP BW/ECC, Cloud technologies all preferred.
  • SAP BTP Certifications (Solution Architect / Integration) preferred.
Responsibilities
  • Solution Design: Work closely with clients and SAP Practice team to understand their business needs and translate them into effective SAP BTP solutions.
  • Technical Expertise: Leverage deep understanding of SAP BTP services including SAP Cloud Platform, data management, analytics, and application development; strong knowledge in various latest SAP products including BTP, FIORI, ECC, S/4HANA, BW/WEB Dispatcher, cloud connectors, Satellite Systems.
  • Integration: Seamlessly integrate SAP BTP with SAP S/4HANA (private cloud) and other SAP and non-SAP enterprise solutions, ensuring end-to-end processes and data flow; provide guidance on system integrations, data flows, and security considerations within the SAP BTP environment; ensure integration of SAP S/4 HANA with other systems and applications.
  • Security and Compliance: Ensure security, compliance, and optimal performance of the SAP BTP environments are well thought through and addressed for the specific client contexts.
  • Collaboration: Work closely across all levels of organization including internal stakeholders, Enterprise Architect and SAP Solution Architects, to execute SAP BTP strategies and collaborate with project stakeholders, business analysts, developers, and functional teams, to gather requirements and translate them into scalable and efficient SAP BTP solutions; expert in collaboratively managing diverse relationships across geography and culture; ability to build, champion, and manage partner relationships as an application service manager.
  • Operational Excellence: Oversee activities related to the BTP Platform and stay updated on industry trends and best practices associated with SAP BTP; conduct system assessments, performance tuning, and optimization; skilled in the management of the monitoring infrastructure and managing platforms.
  • Project Delivery: Lead or participate in full project lifecycles, from requirements gathering to deployment and support; conduct system performance analysis and optimization to ensure optimal utilization of SAP BTP resources across projects and platform; support the development and execution of project plans, timelines, and budgets; manage high-performance team, focused on performance metrics, procedural guidance and continuous process improvement; drive requirement review sessions with partners to develop/deliver MVP requirements, testing strategy, system landscape planning, error handling process, and final project objectives.
  • Compliance Process: Expertise in Agile processes (incident management, change, problem, release management) and Service validation process; drive implementation process including configuring and customizing SAP BTP components to meet business needs; facilitate change management processes and provide training and support to end-users; ensure compliance with industry regulations, standards, and security policies.
  • Communication / Leadership skills: Strong communications verbal & written; creating sound arguments; or to adequately represent both business and IT implications during a Major Service Disruption; strong leadership qualities including being enthusiastic, thoughtful, thorough, decisive, and flexible; make confident decisions and drive results through others while fostering collaboration and innovation; apply best practices for talent management, assessment and diversity and inclusion; ability to work independently and manage multiple projects simultaneously in a fast-paced environment.
  • Problem solving ability: Strong systematic problem-solving experience, a sense of accountability, ownership and drive; interpersonal skills, problem-solving abilities; ability to identify issues and implement effective solutions in a timely manner.
  • Negotiation skills: Maturity, high judgment, negotiation skills, ability to influence, analytical talent and leadership are essential to success in this role.
  • Other skill sets: Focus on business outcomes, strategic thinker with ability to prioritize team goals and activities; seek out and apply feedback toward your own performance and career goals.
Desired Qualifications
  • Master's degree preferred.
  • Knowledge of business processes in SAP/other ERP services preferred.
  • Knowledge on Front end tool using FIORI, UI5, Knowledge on Integration design preferred.
  • SAP BTP App Development & Integration, BTP Architecture and Design, S4 HANA, SAP BW/ECC, Cloud technologies all preferred.
  • SAP BTP Certifications (Solution Architect / Integration) preferred.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 2026 revenue hit $24.1 billion, up 9.9%, raising 2026 forecast to $100.8 billion.
  • Nipocalimab gains FDA Priority Review for autoimmune hemolytic anemia and myasthenia gravis efficacy.
  • Shockwave C2 Aero launches in US and Japan targeting 315 million calcified CAD patients.

What critics are saying

  • Stelara sales plunge 60% to $656 million in Q1 2026 post-patent expiration, creating $2.3 billion hole.
  • Icotyde stalls at 1,500 prescriptions, missing oncology targets by Q3 2026.
  • CAPLYTA faces Invega Sustenna competition, achieving under 10% adoption by mid-2027.

What makes Johnson & Johnson unique

  • J&J unites Innovative Medicine and MedTech under single brand since September 2023.
  • DARZALEX and TREMFYA dominate oncology and immunology with $57 billion pharma sales in 2024.
  • CARTO System leads electrophysiology for 30 years with AI-powered CARTOSOUND SONATA.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Company News

Yahoo Finance
Apr 14th, 2026
J&J's Spravato hits $468M in Q1 sales, signalling upside for psychedelics peers like Atai

Johnson & Johnson's Spravato reported $468 million in first-quarter 2026 sales, up 46% year over year, signalling potential for psychedelics-focused companies like AtaiBeckley Inc., according to Jefferies analysts. The esketamine nasal spray, approved for treatment-resistant depression, is on track to reach an annualised run rate exceeding $1.9 billion. Jefferies maintained that Spravato could hit $3 billion in annual sales by 2027 and $5 billion at peak. Over 200,000 patients have been treated globally, up from 140,000 at the start of 2025. Analysts said Spravato's commercial success demonstrates psychedelics can succeed in mainstream healthcare, with existing treatment infrastructure potentially easing adoption of emerging therapies. They highlighted ATAI's intranasal candidate BPL-003 as fitting seamlessly into Spravato's treatment paradigm.

Yahoo Finance
Apr 14th, 2026
J&J hits $100B milestone with 6.4% growth, eyes double-digit revenue by decade's end

Johnson & Johnson reported 6.4% operational sales growth in Q1 2026, raising full-year guidance to $100.2 billion — the first time the company has reached the $100 billion milestone. The company reaffirmed expectations for double-digit revenue growth by decade's end. Innovative Medicine grew 7.4%, driven by 10 double-digit growing brands including DARZALEX and TREMFYA, despite a 61.7% decline in STELARA due to biosimilar competition. MedTech posted 4.6% growth, led by heart recovery and electrophysiology divisions. The company successfully launched ICOTYDE, the first oral IL-23 peptide for immunology. Management is progressing a $55 billion US manufacturing and R&D investment through 2029, with $12 billion already deployed. The planned separation of its DePuy Synthes Orthopaedics business targets mid-2027 completion.

Business Wire
Apr 7th, 2026
Johnson & Johnson launches VARIPULSE Pro in Europe with 5x faster ablation for atrial fibrillation treatment

Johnson & Johnson has launched VARIPULSE Pro in Europe following CE Mark approval, advancing its pulsed field ablation portfolio for treating atrial fibrillation. The system features a new pulse sequence that operates five times faster than its predecessor whilst maintaining equivalent lesion quality. VARIPULSE Pro integrates with the CARTO 3 mapping system and offers a lower temperature profile whilst preserving the platform's established safety and effectiveness profiles. The company is conducting the VARIPURE multicentre study to generate clinical evidence during the commercial launch phase. The technology addresses atrial fibrillation, the most common cardiac arrhythmia affecting over 50 million people worldwide. Johnson & Johnson will showcase VARIPULSE Pro at the European Heart Rhythm Association annual meeting, with 12-month interim study results to be presented. The device is not currently approved in the United States.

Yahoo Finance
Apr 3rd, 2026
J&J's dividend stays resilient despite market sell-offs and healthcare challenges

Johnson & Johnson has raised $120 million in a Series C round led by Ribbit Capital, valuing the company at $1.45 billion. Sequoia and Kleiner Perkins participated, with Emerson Collective joining as a new backer. The pre-revenue company is developing "Mathematical Superintelligence", an AI system focused on advanced reasoning that claims to eliminate hallucinations by requiring outputs in Lean4 programming language. Its flagship model, Aristotle, achieved top-level performance at the International Mathematical Olympiad in July. Founded in 2023, Harmonic has raised $295 million across three funding rounds in 14 months. The company currently offers Aristotle via a free API and plans to commercialise in safety-critical industries like aerospace and finance.

Yahoo Finance
Apr 1st, 2026
J&J takes over NBTXR3 Phase III as Nanobiotix shifts to Curadigm, secures runway into early 2028

Nanobiotix has transferred full operational and financial responsibility for its NBTXR3 radioenhancer programme to Johnson & Johnson, with Phase III head-and-neck results expected in H1 2027 and Phase II lung cancer data anticipated in early 2027. The company is pivoting towards its Curadigm nanoprimer platform, filing four patents, starting GMP manufacturing and signing over 20 material transfer agreements with partners. Additional Curadigm data is expected before summer's end. An amended Janssen licence removing most Phase III funding obligations, combined with a royalty financing of up to $71 million, extends Nanobiotix's cash runway into early 2028. The company reported EUR 32.6 million revenue in 2025, reduced R&D spending to EUR 23.1 million, and EUR 52.8 million cash at year-end.

INACTIVE